"10.1371_journal.pone.0021772","plos one","2011-07-01T00:00:00Z","Maria C Lebre; Clarissa E Vergunst; Ivy Y K Choi; Sa√Øda Aarrass; Ana S F Oliveira; Tim Wyant; Richard Horuk; Kris A Reedquist; Paul P Tak","Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands; Millennium Pharmaceuticals, Cambridge, Massachusetts, United States of America; Department of Pharmacology, University of California Davis, Davis, California, United States of America","Conceived and designed the experiments: MCL CEV KAR TW RH PPT. Performed the experiments: MCL SA ASFO. Analyzed the data: MCL CEV PPT. Contributed reagents/materials/analysis tools: TW RH. Wrote the paper: MCL CEV IYKC PPT.","The authors have the following competing interests: Prof. Tak has received support from AstraZeneca, Chemocentryx, Millennium, Novartis, Pfizer, and Schering-Plough for conducting clinical trials with chemokine and chemokine receptor antagonists. The above mentioned support is not directly related to this particular study. Dr. T. Wyant is an employee of Millennium Pharmaceuticals and contributed with reagents and with the writing of the manuscript. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2011","07","Maria C Lebre","MCL",9,TRUE,6,3,3,4,TRUE,TRUE,FALSE,0,NA,FALSE
